X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Strides Arcolab with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES SHASUN LTD vs PIRAMAL ENTERPRISES - Comparison Results

STRIDES SHASUN LTD    Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES SHASUN LTD PIRAMAL ENTERPRISES STRIDES SHASUN LTD/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 44.2 11.1 398.3% View Chart
P/BV x 1.1 1.9 57.5% View Chart
Dividend Yield % 0.9 0.9 105.6%  

Financials

 STRIDES SHASUN LTD   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    STRIDES SHASUN LTD
Mar-17
PIRAMAL ENTERPRISES
Mar-18
STRIDES SHASUN LTD/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs1,2753,083 41.3%   
Low Rs9181,902 48.3%   
Sales per share (Unadj.) Rs389.6589.7 66.1%  
Earnings per share (Unadj.) Rs28.0284.0 9.8%  
Cash flow per share (Unadj.) Rs48.9310.5 15.7%  
Dividends per share (Unadj.) Rs4.5025.00 18.0%  
Dividend yield (eoy) %0.41.0 40.9%  
Book value per share (Unadj.) Rs303.11,467.0 20.7%  
Shares outstanding (eoy) m89.42180.27 49.6%   
Bonus/Rights/Conversions ESOPIS-  
Price / Sales ratio x2.84.2 66.6%   
Avg P/E ratio x39.28.8 446.7%  
P/CF ratio (eoy) x22.48.0 279.3%  
Price / Book Value ratio x3.61.7 212.9%  
Dividend payout %16.18.8 182.8%   
Avg Mkt Cap Rs m98,036449,332 21.8%   
No. of employees `0005.86.8 84.8%   
Total wages/salary Rs m5,88119,881 29.6%   
Avg. sales/employee Rs Th6,005.915,535.6 38.7%   
Avg. wages/employee Rs Th1,014.02,905.4 34.9%   
Avg. net profit/employee Rs Th431.27,482.5 5.8%   
INCOME DATA
Net Sales Rs m34,834106,310 32.8%  
Other income Rs m1,6862,595 65.0%   
Total revenues Rs m36,520108,906 33.5%   
Gross profit Rs m6,42851,599 12.5%  
Depreciation Rs m1,8724,773 39.2%   
Interest Rs m2,26929,783 7.6%   
Profit before tax Rs m3,97319,638 20.2%   
Minority Interest Rs m02,801 0.0%   
Prior Period Items Rs m40-   
Extraordinary Inc (Exp) Rs m-1,0060-   
Tax Rs m470-28,764 -1.6%   
Profit after tax Rs m2,50151,203 4.9%  
Gross profit margin %18.548.5 38.0%  
Effective tax rate %11.8-146.5 -8.1%   
Net profit margin %7.248.2 14.9%  
BALANCE SHEET DATA
Current assets Rs m38,165118,154 32.3%   
Current liabilities Rs m30,402462,260 6.6%   
Net working cap to sales %22.3-323.7 -6.9%  
Current ratio x1.30.3 491.1%  
Inventory Days Days7727 291.0%  
Debtors Days Days10447 224.5%  
Net fixed assets Rs m37,639113,727 33.1%   
Share capital Rs m894361 248.0%   
"Free" reserves Rs m26,210264,093 9.9%   
Net worth Rs m27,105264,454 10.2%   
Long term debt Rs m16,377242,206 6.8%   
Total assets Rs m81,168726,834 11.2%  
Interest coverage x2.81.7 165.8%   
Debt to equity ratio x0.60.9 66.0%  
Sales to assets ratio x0.40.1 293.4%   
Return on assets %5.911.1 52.7%  
Return on equity %9.219.4 47.7%  
Return on capital %12.110.3 116.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m13,46515,110 89.1%   
Fx outflow Rs m4,0764,298 94.8%   
Net fx Rs m9,38910,813 86.8%   
CASH FLOW
From Operations Rs m2,881-159,666 -1.8%  
From Investments Rs m-7,051-17,677 39.9%  
From Financial Activity Rs m3,382186,503 1.8%  
Net Cashflow Rs m-7889,364 -8.4%  

Share Holding

Indian Promoters % 27.7 52.9 52.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 4.0 945.0%  
FIIs % 8.6 26.6 32.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 16.5 157.0%  
Shareholders   56,241 93,274 60.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES SHASUN LTD With:   SHASUN PHARMA  WYETH LTD  TORRENT PHARMA  ALEMBIC LTD  DR. REDDYS LAB  

Compare STRIDES SHASUN LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 290 Points; Realty and PSU Stocks Witness Selling(Closing)

After opening the day on a negative note, share markets in India continued their downtrend throughout the day and ended in red.

Related Views on News

STRIDES SHASUN LTD Announces Quarterly Results (1QFY19); Net Profit Down 57.5% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, STRIDES SHASUN LTD has posted a net profit of Rs 38 m (down 57.5% YoY). Sales on the other hand came in at Rs 7 bn (down 21.2% YoY). Read on for a complete analysis of STRIDES SHASUN LTD's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY19); Net Profit Down 152.5% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 1 bn (down 152.5% YoY). Sales on the other hand came in at Rs 29 bn (up 28.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

As the Rupee Takes a Record Plunge, These Pharma Stocks Gain the Most(Sector Info)

Sep 5, 2018

Most pharma stocks were trading with gains amid rupee's fresh fall. Does that mean pharma stocks are back in vogue?

Why Arun Jaitley's Demonetisation Defence Doesn't Add Up(Vivek Kaul's Diary)

Sep 5, 2018

The tax collected has gone up a little but the question is at what cost.

The Cream of Small Cap Stocks(Profit Hunter)

Sep 5, 2018

Akin to skimming the cream off milk, one needs to learn to skim the cream off small cap stocks.

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES SHASUN LTD SHARE PRICE


Sep 18, 2018 (Close)

TRACK STRIDES SHASUN LTD

  • Track your investment in STRIDES SHASUN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES SHASUN LTD

STRIDES SHASUN LTD 8-QTR ANALYSIS

COMPARE STRIDES SHASUN LTD WITH

MARKET STATS